PHVS-416 is under clinical development by Pharvaris and currently in Phase III for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to GlobalData, Phase III drugs for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how PHVS-416’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PHVS-416 overview
Deucrictibant (PHVS-416) is under development for the treatment and prevention of hereditary angioedema (HAE). It is administered through oral route in the form of immediate-release (IR) softgel capsule. The drug candidate acts by targeting B2 bradykinin receptor (BDKRB2).
Pharvaris overview
Pharvaris, formerly Pharvaris BV, is a biopharmaceutical company. It discovers and develops novel therapies for the treatment of hereditary angioedema and other bradykinin B2-receptor-mediated indications. The company is investigating PHA121, an oral small-molecule bradykinin B2 receptor antagonist to treat hereditary angioedema (HAE). It is also evaluating and PHVS416, a softgel capsule formulation; and PHVS719, a tablet formulation for prophylactic treatment of HAE; Pharvaris works in collaboration with pharmaceutical and Biopharmaceutical to develop its products. The company has operational presence in Switzerland and the US. Pharvaris is headquartered in Leiden, Zuid-Holland, the Netherlands.
For a complete picture of PHVS-416’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
